Table 2.

Tobacco abstinence outcomes

	Varenicline	Placebo	p value	Percentage Point Difference	95% CI
Seven-day point prevalence abstinence measure	n=57	n=55
Primary outcome: CO-verified abstinence at 12 weeks, missing = smoking, % (n)*	10.5 (6)	0 (0)	0.03	10.5	4.4 – 19.3
CO-verified abstinence at 12 weeks, multiple imputation for missing data, % (n)†	11.2 (6)	0 (0)	0.02	11.2	4.4 – 13.6
Secondary outcome: CO-verified abstinence at 24 weeks, missing = smoking, % (n)‡	5.3 (3)	0 (0)	0.24	5.3	0.9 – 11.8
CO-verified abstinence at 24 weeks, multiple imputation for missing data, % (n)†	6.8 (3.9)	0 (0)	0.14	6.7	0.9 – 15.4

^*Primary outcome: 7 day point prevalence abstinence at 12 w eeks, biochemically verified w ith CO<8 p.p.m., w ith missing considered smoking

^†Sensitivity analyses of CO-verified 7 day point prevalence abstinence outcomes using multiple imputation models with fully conditional specification for missing data

^‡Secondary outcome: 7 day point prevalence abstinence at 24 weeks, biochemically verified with CO<8 p.p.m., with missing considered smoking